Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review

Angie Raad,Maria Rizzo,Katherine Appiah,Isabella Kearns,Luis Hernandez

DOI: https://doi.org/10.1007/s40273-024-01362-2

2024-03-16

PharmacoEconomics

Abstract:Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with up to 32% of patients with NSCLC harboring an epidermal growth factor receptor (EGFR) mutation. NSCLC harboring an EGFR mutation has a dedicated treatment pathway, with EGFR tyrosine kinase inhibitors and platinum-based chemotherapy often being the therapy of choice.

pharmacology & pharmacy,health care sciences & services,health policy & services,economics

What problem does this paper attempt to address?

The problem this paper attempts to address is to systematically review and summarize economic models used for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying epidermal growth factor receptor (EGFR) mutations, and to identify areas for future model improvement.

Specifically, the objectives of the study include:
1. **Systematic Review**: To comprehensively evaluate published economic models that are used to assess first-line treatment for patients with locally advanced or metastatic NSCLC carrying EGFR mutations.
2. **Summarize Methods and Structure**: To summarize the methods and structure of these economic models, particularly the conceptualization, structure, uncertainty assessment, validation, and transparency of the models.
3. **Identify Areas for Improvement**: To identify shortcomings in existing models in terms of structural choices, sensitivity analysis, and validation, in order to enhance the effectiveness and reliability of future models, thereby better guiding medical decision-making.

Through these objectives, the study aims to provide best practices for future economic evaluation models, particularly in the application to rare diseases.